SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : analysts and calls -- ML
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (232)7/4/2007 3:54:11 PM
From: tom pope   of 238
 
They stick to their guns and blow off the news. I see their price objective is now 27, though. Good luck:

No material impact on ALTU-135 orphan drug revocation
In a filing with the SEC, Altus announced that the FDA is revoking the orphan
drug designation for ALTU-135, currently in phase III development for the
treatment of malabsorption due to pancreatic insufficiency. The revocation would
have no material impact, and in fact highlights the potential for expanded use of
ALTU-135. Maintain Buy.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News